OncoMatch/Clinical Trials/NCT06406634
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
Is NCT06406634 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Cadonilimab and Lenvatinib for hepatocellular carcinoma.
Treatment: Cadonilimab · Lenvatinib — This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage IIIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior exposure to any agent targeting T cell costimulation or immune checkpoint pathways (e.g., anti-PD 1, anti-PD L1, anti-PD L2, anti-CTLA 4, anti CD137 or anti-OX40 antibody, etc)
Lab requirements
Blood counts
ANC ≥1.5x10^9/L without G-CSF in last 14 days; Platelets ≥75×10^9/L without transfusion in last 14 days; Hemoglobin ≥8.5 g/dL without transfusion or erythropoietin in last 14 days; Good coagulation: INR ≤ 2 or aPTT ≤ 1.5x ULN
Kidney function
Serum creatinine ≤1.5 × ULN; Urine protein ≤(++) , or 24-hour urine protein quantification <1 g
Liver function
Serum total bilirubin (TBL) ≤2 × ULN; AST and ALT ≤5× ULN; Child-Pugh A or B
Adequate organ and marrow function, as defined below； 1) Absolute neutrophil count (ANC) ≥1.5x109/L without granulocyte colony-stimulating factor in the last 14 days； 2) Platelets ≥75×109/L without transfusion in the last 14 days； 3) Hemoglobin ≥8.5 g/dL without transfusion or erythropoietin use in the last 14 days； 4) Serum total bilirubin (TBL) ≤2 × ULN； 5) AST and ALT ≤5× ULN； 6) Serum creatinine ≤1.5 × upper limit of normal (ULN)； Urine protein ≤(++) , or 24-hour urine protein quantification less than 1 g； 7) Good coagulation, defined as the international normalized ratio (INR) ≤ 2， or activated partial prothrombin time (PT) ≤ 1.5 times ULN；
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06406634 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIIA is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages